Literature DB >> 15569004

Insight into the pathogenesis of sporadic basal cell carcinoma.

Zuzana Holíková1, Daniela Massi, Torello Lotti, Jana Hercogová.   

Abstract

Sporadic basal cell carcinoma (BCC) is the commonest human cancer. Although its aggressiveness is low and metastatic potential negligible, the increasing incidence of the tumor in the Western world drives attention to its pathogenesis. In 1996, germ-line mutations in the patched receptor of the Sonic hedgehog (Shh) signaling pathway were described in the Gorlin-Goltz syndrome in association with multiple nevoid BCCs. Later, the aberrant activation of the Shh was identified in sporadic BCCs as well. Recently, the role of other tumor suppressors and DNA repair gene mutations and their relationship with UV radiation-induced DNA damage have been elucidated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15569004     DOI: 10.1111/j.1365-4632.2004.02319.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  4 in total

1.  Nevoid basal cell carcinoma syndrome (Gorlin-Goltz syndrome). Case report.

Authors:  G Fini; E Belli; E Mici; P Virciglio; L M Moricca; L D'Itri; A Leonardi; M S Malavenda; D Krizzuk; R Merola; A Maturo; V Pasta
Journal:  G Chir       Date:  2013 May-Jun

Review 2.  Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response.

Authors:  Donatella Gambini; Emanuela Passoni; Gianluca Nazzaro; Giada Beltramini; Gianluca Tomasello; Michele Ghidini; Elisabetta Kuhn; Ornella Garrone
Journal:  Front Med (Lausanne)       Date:  2022-06-14

3.  Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease.

Authors:  Daniela Göppner; Martin Leverkus
Journal:  J Skin Cancer       Date:  2010-12-29

4.  Evaluation of the 'Hedgehog' signaling pathways in squamous and basal cell carcinomas of the eyelids and conjunctiva.

Authors:  Ali Riza Cenk Celebi; Hayyam Kiratli; Figen Soylemezoglu
Journal:  Oncol Lett       Date:  2016-05-25       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.